나노포어 기술 시장 규모, 점유율, 동향 및 예측 : 제품별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global nanopore technologies market size was valued at USD 341.8 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 834.8 Million by 2034, exhibiting a CAGR of 10.12% during 2026-2034. North America currently dominates the market, holding a significant market share of over 41.2 % in 2025. The global market is majorly driven by rising demand for precision medicine, real-time and cost-effective DNA/RNA sequencing, expanding applications in diagnostics and drug discovery, advancements in sequencing accuracy and portability, increasing research investments, and growing adoption in genomics, proteomics, and personalized healthcare solutions.

The global market is primarily driven by the increasing demand for precision medicine and genetic analysis as nanopore technology offers real-time, cost-effective sequencing of DNA and RNA. Moreover, the growing applications in diagnostic tools, drug discovery, and personalized medicine are fueling market growth. Additionally, ongoing advancements in sequencing accuracy, reduced costs, and improved throughput capabilities are further creating a positive nanopore technologies market outlook. Moreover, the rising need for rapid, portable diagnostics and the ongoing efforts in the fields of genomics and proteomics are also contributing to the market's expansion, along with increased research investments. For instance, on January 13, 2025, Truveta announced a USD 320 Million investment from Regeneron Pharmaceuticals, Illumina, and 17 U.S. health systems to create the world's largest genetic database. This initiative aims to compile 10 million genomic sequences, enhancing drug discovery and patient care. Regeneron will contribute USD 120 Million and conduct the sequencing, while Illumina will invest USD 20 Million. The project will extend this work in scale and diversity to include patient-consented, anonymized medical records and specimens.

The United States stands out as a key regional market, primarily driven by the prevalence of chronic diseases such as cancer and cardiovascular conditions is rising. For instance, U.S. Food & Drug Administration reported that seven of the ten major causes of death in the U.S. are common chronic diseases (CCDs), with diet-related illnesses such as cardiovascular disease, diabetes, obesity, and certain cancers contributing significantly. The U.S. ranks behind 42 countries in diet-related disease rates, and 28 million Americans continue to smoke, which is fueling the need for unique therapeutic intervention. increasing research activities in the areas of microbiology and environmental monitoring where nanopore devices are used for the detection of pathogens and contaminants. In addition, the integration of artificial intelligence with nanopore technology is improving the data analysis and the diagnostic accuracy. Furthermore, the healthcare and agricultural sector demands immediate, efficient, and on-site tests, which is contributing to market growth. The country's strong healthcare infrastructure and favorable government initiatives for the support of biotech innovations are accelerating the adoption of nanopore technologies further.

NANOPORE TECHNOLOGIES MARKET TRENDS:

Expanding Clinical Applications

Nanopore sequencing is increasingly becoming popular in clinical diagnostics as it has the capability to sequence long DNA or RNA strands in real-time. Its transformative power is in infectious disease diagnostics, where pathogen identification becomes faster and greatly improves patient outcome. Applications in cancer genomics are increasing as nanopore technologies enable the analysis of structural variants, methylation patterns, and gene fusions that are important for the formulation of personalized treatment strategies. A study published in September 2024 discusses the application of Oxford Nanopore sequencing to assess the possible transmission of infections within a hospital setting, but it does not provide data on the number of hospitals using the technology. Another study from June 2024 focuses on benchmarking and quality control for nanopore sequencing in a single quaternary hospital in New Zealand, indicating that the technology is being implemented in specific institutions. In contrast to conventional sequencing, nanopore technology does not require amplification or extensive sample preparation, making it very efficient for clinical use. Its versatility and declining costs are setting nanopore sequencing as a core technology in precision medicine. The adaptability of the technology to address emerging healthcare needs, such as monitoring pandemics and managing antimicrobial resistance, further emphasizes its potential to revolutionize clinical applications and drive sustained nanopore technologies market growth.

Advancements in Portable Devices

Nanopore technologies are revolutionizing the accessibility and usability of genetic analysis through rapid developments in portable sequencing devices. The Oxford Nanopore's MinION has been popular in its compact form, affordability, and real-time delivery of sequencing results. As of 2023, the MinION device has been used in over 100 countries, highlighting its global reach. Researchers and healthcare providers are empowered by these portable devices to conduct onsite genetic analyses within diverse environments- remote and resource limited. This portability is significantly beneficial in applications such as field-based pathogen surveillance, agricultural genomics, and environmental monitoring as it is impractical to set up a whole laboratory in the field. Besides that, the integration of cloud-based analysis platforms with portable devices tends to enhance their functionality, allowing real-time data sharing and collaboration. The increasing emphasis on the development of user-friendly and robust devices is democratizing access to sequencing technologies, expanding nanopore technologies market share.

Rising Investments in Genomic Research

Increasing investment by governments and academic institutions, in addition to private enterprises, into genomic research is a growth factor for the nanopore technologies market. According to recent data, the National Institutes of Health (NIH) has allocated up to USD 27 Million to establish genomics-enabled learning health systems and has earmarked USD 5.4 Million for the first year to integrate genomics into patient care. These initiatives underscore the growing emphasis on leveraging advanced sequencing technologies, such as nanopore platforms, for improving healthcare outcomes. These investments are expected to help better understand the nature of genetic information and what that might mean for health, agriculture, and environmental sciences. Funding initiatives such as the Human Genome Project and national genomic research programs in countries such as the U.S. and China are fueling innovation in sequencing technologies, including nanopore-based platforms. Private-sector players are also channeling significant resources into the development of cutting-edge nanopore devices to meet the rising demand for faster, cheaper, and more accurate sequencing solutions. This influx of funding is accelerating technological advancements and enabling new applications in personalized medicine, synthetic biology, and more. The steady growth in research funding underscores the pivotal role nanopore technologies play in the broader genomics ecosystem.

NANOPORE TECHNOLOGIES INDUSTRY SEGMENTATION:

Analysis by Product:

• Instruments
  • Portable
  • Benchtop
• Consumables

Consumables lead the market with around 55.0% of market share in 2025. The dominance of consumables in the nanopore technologies market is driven by the recurring demand for sequencing processes, such as flow cells, reagents, and sample preparation kits. These are essential components that ensure the performance and accuracy of nanopore devices, and thus, research institutions, healthcare providers, and diagnostic labs continue to purchase them. The growing need for personalized medicine and real-time sequencing applications ensures the sustained demand for consumables in the nanopore technologies market. Moreover, consumable design is being improved, with higher throughput flow cells and specialized reagents that are improving efficiency and lowering costs, which further increases adoption.

Analysis by Application:

• DNA Sequencing
• RNA Sequencing
• Others

DNA sequencing leads the market with around 60.0% of market share in 2025. DNA sequencing plays a vital role in the nanopore technologies market as it gives real-time and long-read sequences that provide invaluable information about genetics. Moreover, the technology is cost-effective and portable for wide use in research and clinic settings, thereby making the nanopore market valuable. These are especially applied in the determination of complex variations, structural rearrangements, and epigenetic modifications. The growing demand for precision medicine and improvements in the speed and accuracy of sequencing will further support the application of this technology in the diagnosis of diseases, personalized treatment, and studies of evolution. Also, the greater integration of nanopore DNA sequencing in agriculture and microbiology strengthens its market leadership.

Analysis by End User:

• Hospitals and Clinics
• Research Institutes
• Others

Research institutes lead the market with around 45.3% of market share in 2025. The market for nanopore technologies is dominated by research institutes due to the substantial contribution these institutes have toward genomic studies, molecular biology, and biotechnology. These institutes significantly apply nanopore sequencing to diverse applications such as genetic mutations, rare diseases, and the study of microbiomes. This nanopore platform's flexibility and scalability provide advanced research capabilities in areas such as transcriptomics and epigenetics. The development of grants and government funding for scientific research also increases adoption, together with cooperation by a large number of research institutes, which implements innovation through improved sequencing accuracy and efficiency, resulting in their dominant position in the market.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 41.2% due to its superior healthcare infrastructure and substantial investments in biotechnology and genomic research. The region benefits from the presence of key industry players and has vast government funding for precision medicine and genomics. Furthermore, the acceptance of innovative technologies, including real-time sequencing and AI integration, is also speeding up the growth of the market. The demand from individualized medicines, diagnostics, agricultural, and environmental sectors forms further support for the market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NANOPORE TECHNOLOGIES MARKET ANALYSIS

In 2025, the US accounted for around 78.90% of the total North America nanopore technologies market. The U.S. nanopore technologies market is rising fast with immense investment in genomics and healthcare innovations. The NIH has granted up to USD 27 Million to create a network of genomics-enabled learning health systems and allocated USD 5.4 Million for the first year to embed genomics in patient care. All these efforts are enriching the application of nanopore-based sequencing in real-time clinical decision-making and disease management. Companies such as Oxford Nanopore Technologies are seizing the momentum with high-end, low-cost sequencing solutions. Market growth is driven by precision medicine and increased funding in genomic research. Through its collaborations with industries and the supportive role of the U.S. government towards innovative biotechnology activities, the United States is establishing its position as one of the global leaders in nanopore technologies.

EUROPE NANOPORE TECHNOLOGIES MARKET ANALYSIS

The nanopore technologies market in Europe is growing steadily with the rise in investments in genomic research and healthcare initiatives. Eurostat statistics revealed that the EU has set aside EUR 1.8 Billion (USD 1.9 Billion) in 2022 toward biotech innovation, most of which targets nanopore sequencing. The UK and Germany are the leaders, and institutions such as the Francis Crick Institute drive cutting-edge research. The adoption of nanopore technologies in next-generation sequencing is also on the rise in clinical diagnostics, especially in rare diseases. Moreover, personalized medicine has become a major emphasis in the EU, such as through Horizon Europe, further fostering nanopore technologies market demand. . With biotech growth being supported by regulatory frameworks, Europe will be an excellent player in the global market of nanopore technology.

ASIA PACIFIC NANOPORE TECHNOLOGIES MARKET ANALYSIS

The Asia Pacific nanopore technologies market is growing rapidly due to increased investments in genomics and healthcare advancement. Chinese nanopore sequencing company Qitan Tech raised a Series C round of RMB 700 Million (or about USD 103.7 Million) back in January 2023. This is significant private sector interest in the area. Countries such as China and India have focused heavily on genomic research and clinical applications, with initiatives such as "Make in India" enhancing domestic innovation in sequencing technologies. Further pushing market growth will be the increasing interest in personalized medicine and infectious disease detection in Japan and South Korea. Acceleration of innovation through collaborative partnerships between local and global players, increased government funding, and development of healthcare infrastructure are making the region a significant contributor to the global nanopore technologies market.

LATIN AMERICA NANOPORE TECHNOLOGIES MARKET ANALYSIS

Latin American nanopore technologies are growing with investments in genomics and biotechnology. For example, the National Fund for Scientific and Technological Development in Brazil was given more resources in the 2023 fiscal year according to Law No. 14.577 by Global Trade Alert. These resources support scientific research and innovation, including advancements in genomics. Countries such as Mexico and Colombia are also focusing on genomic research for regional health challenges, which is propelling the demand for innovative sequencing technologies. Private investments along with government initiatives are encouraging the collaboration of local researchers with international players, which will fuel the market growth. Further, the developing healthcare infrastructure along with the increased focus on precision medicine is emerging Latin America as a new hub in the global nanopore technologies market.

MIDDLE EAST AND AFRICA NANOPORE TECHNOLOGIES MARKET ANALYSIS

Nanopore technologies market in the Middle East and Africa is picking up as more investment in healthcare innovation takes place. For instance, the UAE's federal budget for 2023 had AED 63.066 Billion, or about USD 17.17 Billion, allocated to total expenditures. Of that amount, AED 4.8 Billion, or about USD 1.31 Billion, was allocated to healthcare and community protection (Ministry of Finance). The Emirati Genome Program also focuses on the complete sequencing of the Emirati genome to improve personalized healthcare. All these programs indicate the heavy incorporation of cutting-edge genomic technology within the health sector. Collaboration with international biotech companies and increasing investment in sequencing technologies in precision medicine is driving growth in the market. Expanding health infrastructure and government-sponsored research programs put the region as a fast-growing contributor to the global landscape of nanopore technologies.

COMPETITIVE LANDSCAPE:

The market is characterized by the presence of numerous established players and emerging innovators striving to enhance sequencing technologies. Companies are heavily investing in research and development to improve accuracy, throughput, and affordability, fostering a dynamic environment of technological advancements. Strategic partnerships, licensing agreements, and collaborations with academic institutions are prevalent, facilitating innovation and expanding application areas. In addition, market participants are focusing on miniaturization and portability of devices, catering to the rising demand for point-of-care diagnostics and field-based testing solutions across various sectors. Notably, on November 5, 2024, Oxford Nanopore Technologies announced its partnership with UK health agencies to speed up pathogen screening across up to 30 NHS sites. The partnership will identify severe respiratory infections and recommend treatments within six hours of sample collection, thus bolstering early warning systems for pandemic threats. Oxford Nanopore's long-read sequencing technology will be used in the project to improve monitoring of emerging bacterial and viral threats and the spread of drug-resistant pathogens.

The report provides a comprehensive analysis of the competitive landscape in the nanopore technologies market with detailed profiles of all major companies, including:

• Agilent Technologies Inc.
• Cyclomics BV
• Electronic Biosciences Inc.
• Inanobio Inc.
• Nabsys Inc.
• Ontera Inc.
• Oxford Nanopore Technologies Limited
• Pacific Biosciences of California Inc.
• Quantapore Inc.
• Roche Holding AG
• Tracxn Technologies Limited

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the nanopore technologies market?

2. What is the future outlook of nanopore technologies market?

3. What are the key factors driving the nanopore technologies market?

4. Which region accounts for the largest nanopore technologies market share?

5. Which are the leading companies in the global nanopore technologies market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Nanopore Technologies Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Portable
    • 6.1.2.2 Benchtop
  • 6.1.3 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 DNA Sequencing
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 RNA Sequencing
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Agilent Technologies Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Cyclomics BV
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Electronic Biosciences Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Inanobio Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Nabsys Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Ontera Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Oxford Nanopore Technologies Limited
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Pacific Biosciences of California Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Quantapore Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Roche Holding AG
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Tracxn Technologies Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio